Drug Profile

EVT 894

Alternative Names: EVT-894; SAR-440894

Latest Information Update: 10 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi
Developer Duke Clinical Research Institute; Evotec SE; National Institute of Allergy and Infectious Diseases
Class Antivirals; Monoclonal antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Aug 2024 National Institute of Allergy and Infectious Diseases in collaboration with completes a phase I trial in Chikungunya-virus-infections in USA (IV, Infusion) (NCT04441905)
18 Jan 2024 EVT 894 is still in phase-I development in Chikungunya-virus-infections in USA (IV, Infusion) (NCT04441905)
28 Nov 2023 No recent reports of development identified for phase-I development in Chikungunya-virus-infections(In volunteers) in USA (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com